Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro

European Journal of Pharmacology

Volumn 659, Issue 2-3, 2011, Pages 108-113

  Gao, Aili ^a   Liang, Hongsheng ^b   Wang, Xiangjing ^a   Zhang, Xiangtong ^b   Jing, Meng ^b   Zhang, Ji ^a   Yan, Yijun ^a   Xiang, Wensheng ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

MCF 7 adr; Milbemycin; Multidrug resistance; P glycoprotein

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MILBEMYCIN BETA14; MILBEMYCIN DERIVATIVE; SECOMILBEMYCIN D; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG ISOLATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; FERMENTATION; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; MDR1 GENE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STREPTOMYCES; STREPTOMYCES BINGCHENGGENSIS;

CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; MACROLIDES; P-GLYCOPROTEIN; RHODAMINE 123;

EID: 79955936696     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.023     Document Type: Article

References (36)

1. Barthomeuf, C., Grassi, J., Demeule, M., Fournier, C., Boivin, D., Béliveau, R., 2005. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother. Pharmacol. 56, 173-181.
2. Burg, R.W., Miller, B.M., Baker, E.E., Birnbaum, J., Currie, S.A., Hartman, R., Kong, Y.L., Monaghan, R.L., Olson, G., Putter, I., Tunac, J.B., Wallick, H., Stapley, E.O., Oiwa, R., Omura, S., 1979. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob. Agents Chemother. 15, 361-367.
3. Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., Mitchell, J.B., 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47, 936-942. (Pubitemid 17027905)
4. Choudhuri, S., Klaassen, C.D., 2006. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25, 231-259.
5. Dider, A., Loor, F., 1996. The abamectin derivative ivermectin is potent P glycoprotein inhibitor. Anti-cancer Drugs 7, 745-751. (Pubitemid 26388764)
6. Fojo, T., Bates, S., 2003. Strategies for reversing drug resistance. Oncogene 22, 7512-7523. (Pubitemid 37487173)
7. Gao, A.L., Wang, X.J., Xiang, W.S., Liang, H.S., Gao, J.G., Yan, Y.J., 2010. Reversal of P-glycoprotein mediated multidrug resistance in vitro by doramectin and nemadectin. J. Pharm. Pharmacol. 62, 393-399.
8. Gottesman, M.M., Pastan, I., 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 335-427.
9. Huang, M., Jin, J., Sun, H., Liu, G.T., 2008. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother. Pharmacol. 62, 1015-1026.
10. Izquierdo, M.A., Scheffer, G.L., Flens, M.J., Schroeijers, A.B., ven der Valk, P., Scheper, R.J., 1996. Major vault protein LRP-related multidrug resistance. Eur. J. Cancer 32A, 979-984.
11. Jin, J., Wang, F.P., Wei, H.L., Liu, G.T., 2005. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother. Pharmacol. 55, 179-188.
12. Kim, J.H., Yun, J., Sohng, J.K., Cha, J.M., Choi, B.C., Jeon, H.J., Kim, S.H., Choi, C.H., 2007. Di (2-ethylhexyl)phthalate leached from medical PVC devices serves as a substrate and inhibitor for the P-glycoprotein. Environ. Toxicol. Pharmacol. 23, 272-278.
13. Klamt, F., Passos, D.T., Castro, M.A., Gelain, D.P., Grivicich, I., Moreira, J.C., 2008. Inhibition of MDR1 expression by retinol treatment increases sensitivity to etoposide (VP16) in human neoplasic cell line. Toxicol. In Vitro 22, 873-878.
14. Korystov, Y.N., Ermakova, N.V., Kublik, L.N., Levitman, M.Kh., Shaposhnikova, V.V., Mosin, V.A., Drinyaev, V.A., Kruglyak, E.B., Novik, T.S., Sterlina, T.S., 2004. Avermectins inhibit multidrug resistance of tumor cells. Eur. J. Pharmacol. 493, 57-64.
15. Krishna, R., Mayer, L.D., 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283.
16. Leslie, E.M., Deeley, R.G., Cole, S.P., 2005. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204, 216-237.
17. Lespine, A., Dupuy, J., Orlowski, S., Nagy, T., Glavinas, H., Krajcsi, P., Alvinerie, M., 2006. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem. Biol. Interact. 159, 169-179.
18. Lespine, A., Martin, S., Dupuy, J., Roulet, A., Pineau, T., Orlowski, S., Alvinerie, M., 2007. Interaction ofmacrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur. J. Pharm. Sci. 30, 84-94.
19. Li, X., Sun, B., Zhu, C.J., Yuan, H.Q., Shi, Y.Q., Gao, J., Li, S.J., Lou, H.X., 2009. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Toxicol. In Vitro 23, 29-36.
20. Liu, Y.H., Di, Y.M., Zhou, Z.W., Mo, S.L., Zhou, S.F., 2010. Multidrug resistance associated proteins and implications in drug development. Clin. Exp. Pharmacol. Physiol. 37, 115-120.
21. Maliepaard, M., van Gastelen, M.A., de Jong, L.A., Pluim, D., van Waardenburg, R.C., Ruevekamp-Helmers, M.C., Floot, B.G., Schellens, J.H., 1999. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59, 4559-4563. (Pubitemid 29428958)
22. Nara, T., Katoh, N., Inoue, K., Yamada, M., Arizono, N., Kishimoto, S., 2009. Eosinophilic folliculitis with a Demodex folliculorum infestation successfully treated with ivermectin in a man infected with human immunodeficiency virus. Clin. Exp. Dermatol. 34, e981-e983.
23. Perez, M., Blazquez, A.G., Real, R., Mendoza, G., Prieto, J.G., Merino, G., Alvarez, A.I., 2009. In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chem. Biol. Interact. 180, 106-112.
24. Ponce de León, V., Barrera-Rodríguez, R., 2005. Changes in P-glycoprotein activity are mediated by the growth of a tumour cell line as multicellular spheroids. Cancer Cell Int. 5, 20.
25. Prichard, R.K., 2005. Is anthelmintic resistance a concern for heartworm control? What can we learn from the human filariasis control programs? Vet. Parasitol. 133, 243-253. (Pubitemid 41405857)
26. Qi, J., Wang, S.B., Liu, G.Y., Peng, H., Wang, J.H., Zhu, Z.P., Yang, C.Z., 2004. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. BBRC 319, 1124-1131. (Pubitemid 38759528)
27. Shen, F., Bailey, B.J., Chu, S., Bence, A.K., Xue, X., Erickson, P., Safa, A.R., Beck, W.T., Erickson, L.C., 2009. Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J. Pharmacol. Exp. Ther. 330, 423-429.
28. Shi, Y.Q., Qu, X.J., Liao, Y.X., Xie, C.F., Cheng, Y.N., Li, S., Lou, H.X., 2008. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Eur. J. Pharmacol. 584, 66-71.
29. Sikic, B.I., Fisher, G.A., Lum, B.L., Halsey, J., Beketic-Oreskovic, L., Chen, G., 1997. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40, S13-S19.
30. Theis, J.G., Chan, H.S., Greenberg, M.L., Malkin, D., Karaskov, V., Moncica, I., Koren, G., Doyle, J., 2000. Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. Med. Pediatr. Oncol. 34, 242-249.
31. Wang, R.B., Kuo, C.L., Lien, L.L., Lien, E.J., 2003. Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther. 28, 203-238.
32. Wang, X.J., Wang, J.D., Xiang, W.S., Zhang, J., 2009. Three new milbemycin derivatives from Streptomyces bingchenggensi. J. Asian Nat. Prod. Res. 11, 597-603.
33. Werle, M., 2008. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res. 25, 500-511.
34. Xiang, W.S., Wang, J.D., Wang, X.J., Zhang, J., 2007. Two new β-class milbemycins from Streptomyces bingchenggensis: fermentation, isolation, structure elucidation and biological properties. J. Antibiot. 60, 351-356.
35. Xiang, W.S., Gao, A.L., Liang, H.S., Li, C.Y., Gao, J.G., Wang, Q., Shuang, B., Zhang, J., Yan, Y.J., Wang, X.J., 2010. Reversal of P-glycoprotein-mediatedmultidrug resistance in vitro by milbemycin compounds inadriamycin-resistanthuman breast carcinoma (MCF-7/adr) cells. Toxicol. In Vitro 24, 1474-1481.
36. Zhou, Y., Hopper-Borge, E., Shen, T., Huang, X.C., Shi, Z., Kuang, Y.H., Furukawa, T., Akiyama, S., Peng, X.X., Ashby Jr., C.R., Chen, X., Kruh, G.D., Chen, Z.S., 2009. Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol. 77, 993-1001.